The Lancet: Long-term study suggests oral peanut immunotherapy may be more effective in children under four with peanut allergy

Peer-reviewed/randomized controlled trials/person

• The study included 146 peanut-allergic children and measured desensitization (safe intake of 5,000 mg of peanut protein powder in a food challenge following a two-and-a-half-year daily treatment period under the supervision of the investigator) and remission (26 after treatment ended).

  
  

• Among the children receiving oral peanut immunotherapy, 71% (68/96) achieved desensitization compared with 2% (1/50) of the placebo group and 21% (20/96) of the placebo group achieved remission, and The placebo group was 2% (1/50)

  
  

• Further analysis showed that younger children were more likely to achieve remission than older children at the start of treatment

  
  

• In this trial, children were closely supervised and given small amounts of peanut protein powder, which was gradually increased to 2,000 mg per day (equivalent to 6 peanuts)

  
  

article title

Efficacy and safety of oral immunotherapy in children aged 1–3 years with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study